Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

      1. - 36 (Canceled)

      37.   (Withdrawn) A method for selecting optimized glycosylated monoclonal antibodoes, wherein said antibodies have less than 50% of G0F and G1F glycannic structure on their Fcγ, comprising:

      a)   bringing into contact a CD16 expressing effector cells of the immune system, which may or may not be transformed, in a reaction medium in the presence of an antibody and the antigen for said antibody,

      b)   measuring the amount of at least one cytokine produced by the CD16 expressing cell, and

      c)   selecting antibodies for which the level of said cytokine produced is increased by more than 100% compared with the control in the absence of antibody or in the presence of a given antibody as a negative reference.

      38.   (Currently amended) A method for <u>selecting</u> ~~evaluating the effectiveness of~~ a monoclonal ~~or polyclonal~~ antibody, comprising:

      a)   bringing <u>a</u> CD16<u>-transformed</u> ~~receptor-expressing~~ effector <u>cell Jurkat</u> ~~cells,~~ ~~which may be transformed so as to express the~~ CD16 ~~receptor,~~ into ~~contact in~~ a reaction medium with <u>the</u> [[a]] monoclonal ~~(MoAb) or polyclonal~~ antibody and <u>the</u> [[an]] antigen for said antibody, ~~the antibody being activated by the antigen, and the antigen being different from the CD16, and~~

      b)   measuring the amount of <u>IL-2</u> ~~at least one~~ cytokine <u>released,</u> ~~produced by the CD16 expressing cell,~~ and

c)   selecting an antibody for which the level of said IL-2 release is increased by more than 100% compared with a negative control, ~~performing an ADCC assay,~~ wherein the measurement of the amount of IL-2 is linearly correlated to the CD16-specific ~~with an~~ ADCC ~~(antibody-dependent cellular cytotoxicity) type~~ activity, and wherein the negative control is an antibody of the same specificity produced by CHO cells or the absence of the antibody.